Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR17 | Q13304 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.82 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.82 |
| ▸ | MAPT | P10636 | 1/20 | 0.82 |
| ▸ | HPGD | P15428 | 1/20 | 0.82 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.82 |
| ▸ | TSHR | P16473 | 1/20 | 0.82 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.82 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.82 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.57 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gavestinel SCHEMBL30184856 | 1.00 | GPR17 (1.00) | GPR17MEN1KMT2AKDM4EALDH1A1 | |
| Gavestinel SCHEMBL1721070 | 1.00 | GPR17 (1.00) | GPR17MEN1KMT2AKDM4EALDH1A1 | |
| Gavestinel SCHEMBL1995817 | 0.99 | GPR17 (0.98) | GPR17MEN1KMT2AKDM4EALDH1A1 | |
| Gavestinel SCHEMBL1995813 | 0.99 | GPR17 (0.98) | GPR17MEN1KMT2AKDM4EALDH1A1 | |
| Gavestinel SCHEMBL1995818 | 0.99 | GPR17 (0.98) | GPR17MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL8344945 | 0.91 | GPR17 (0.84) | GPR17MEN1KMT2AKDM4EALDH1A1 | |
| Gavestinel SCHEMBL9014837 | 0.90 | KDM4E (1.00) | GPR17MEN1KMT2AKDM4EALDH1A1 | |
| Gavestinel SCHEMBL1720490 | 0.90 | KDM4E (1.00) | GPR17MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL9395908 | 0.88 | GPR17 (0.79) | GPR17MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL9395914 | 0.88 | GPR17 (0.79) | GPR17MEN1KMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 781 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028675-A1 | PRECISION MEDICINE FOR PAIN: DIAGNOSTIC BIOMARKERS, PHARMACOGENOMICS, AND REPURPOSED DRUGS | UNIV INDIANA RES & TECH CORP (US) | 2026-01-29 | — | — | US | claimed |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| WO-2024111636-A1 | AGENT FOR ALLEVIATING CLOZAPINE-INDUCED SIALORRHEA | 国立大学法人千葉大学 | 2024-05-30 | — | — | WO | claimed |
| EP-4297868-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | Hoth Therapeutics, Inc. (US) | 2024-01-03 | — | — | EP | claimed |
| US-20230201193-A1 | COMPOSITION AND METHOD FOR TREATMENT OF DEPRESSION AND PSYCHOSIS IN HUMANS | GLYTECH LLC (US) | 2023-06-29 | — | — | US | claimed |
| WO-2022182658-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. (US) | 2022-09-01 | — | — | WO | claimed |
| US-20220143041-A1 | COMBINED THERAPY FOR NMDAR ANTAGONIST-RESPONSIVE NEUROPSYCHIATRIC DISORDERS | GLYTECH LLC (US) | 2022-05-12 | — | — | US | claimed |
| US-20210128579-A1 | FORMULATIONS FOR TREATMENT OF POST-TRAUMATIC STRESS DISORDER | GLYTECH LLC (US) | 2021-05-06 | — | — | US | claimed |
| US-20210047689-A1 | PRECISION MEDICINE FOR PAIN: DIAGNOSTIC BIOMARKERS, PHARMACOGENOMICS, AND REPURPOSED DRUGS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2021-02-18 | — | — | US | claimed |
| US-20200206219-A1 | COMPOSITION AND METHOD FOR TREATMENT OF DEPRESSION AND PSYCHOSIS IN HUMANS | GLYTECH LLC (US) | 2020-07-02 | — | — | US | claimed |
| US-20070043120-A1 | Therapeutic combination for painful medical conditions | UCB PHARMA GMBH (DE) | 2007-02-22 | — | — | US | claimed |
| US-20060264897-A1 | Apparatus and method for delivering therapeutic and/or other agents to the inner ear and to other tissues | NEUROSYSTEC CORPORATION (US) | 2006-11-23 | — | — | US | claimed |
| WO-2006094674-A1 | NMDA RECEPTOR ANTAGONISTS IN THE MEDICAL INTERVENTION OF METABOLIC DISORDERS | HERMANUSSEN MICHAEL (DE) | 2006-09-14 | — | — | WO | claimed |
| WO-2006079055-A2 | APPARATUS AND METHOD FOR DELIVERING THERAPEUTIC AND/OR OTHER AGENTS TO THE INNER EAR AND TO OTHER TISSUES | NEUROSYSTEC CORPORATION (US) | 2006-07-27 | — | — | WO | claimed |
| EP-1613324-A2 | METHODS FOR THE TREATMENT OF PAIN COMPRISING OPIOID ANTAGONISTS | Pain Therapeutics, Inc. (US) | 2006-01-11 | — | — | EP | claimed |
| US-20050038062-A1 | Methods and materials for the treatment of pain comprising opioid antagonists | PAIN THERAPEUTICS, INC. | 2005-02-17 | — | — | US | claimed |
| WO-2004091593-A2 | METHODS FOR THE TREATMENT OF PAIN COMPRISING OPIOID ANTAGONISTS | PAIN THERAPEUTICS, INC. (US) | 2004-10-28 | — | — | WO | claimed |
| US-6020359-A | INJECTABLE SOLUTION OF 3-(2-(PHENYLCARBAMOYL)ETHENYL)-4,6-DICHLOROINDOLE-2-CARBOXYLIC ACID; GLYCINE ANTAGONIST | GLAXO WELLCOME SPA (IT) | 2000-02-01 | — | — | US | claimed |
| EP-0809514-A1 | PHARMACEUTICAL COMPOSITION FOR PARENTERAL APPLICATION CONTAINING AN INDOLE-CARBOXYLIC ACID | GLAXO WELLCOME S.p.A. (IT) | 1997-12-03 | — | — | EP | claimed |
| WO-1996024376-A1 | PHARMACEUTICAL COMPOSITION FOR PARENTERAL APPLICATION CONTAINING AN INDOLE-CARBOXYLIC ACID | GLAXO WELLCOME S.P.A. (IT) | 1996-08-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028675-A1 | PRECISION MEDICINE FOR PAIN: DIAGNOSTIC BIOMARKERS, PHARMACOGENOMICS, AND REPURPOSED DRUGS | MYLK3, MYL12A, MYLK2 | GPR17 3310/4885MEN1 4427/4885KMT2A 3198/4885 |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | TACR1, ACHE, TACR2 | GPR17 227/4885MEN1 2886/4885KMT2A 1550/4885 |
| US-20070043120-A1 | Therapeutic combination for painful medical conditions | PDE1B, CA2, CACNA1S | GPR17 1299/4885MEN1 1264/4885KMT2A 1606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.